Alcon Research, Ltd.

Alcon, Inc.

Alcon Universal Ltd.

Novartis Ag

Alcon Laboratories, Inc.

Alcon Pharmaceuticals Ltd.

Onkar N Singh

Wesley Wehsin Han

Ernesto J Castillo

Haresh G Bhagat

Suresh Dixit

Masood A Chowhan

Daniel A Gamache

Laman L Alani

G Michael Wall

Rajni Jani

Malay Ghosh

Huixiang Zhang

Joseph Paul Bullock

Michael Wall

Alan L Weiner

Francisco Javier Galán

Ruma P Sarkar

Cody Yarborough

Nuria Carreras Perdiguer

Núria Carreras Perdiguer

Suresh C Dixit

The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.

High concentration olopatadine ophthalmic composition

Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.

Olopatadine formulations for topical nasal administration

Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.

Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate

Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.

Olopatadine formulations for topical administration

Sustained release suspension formulations for ophthalmic, otic and nasal administration are disclosed. The formulations comprise a basic active, a cation exchange resin, and a combination of a polymeric suspending agents to provide superior resuspendability.

Sustained release ophthalmic, otic and nasal suspension

This invention relates to reduced stinging, sustained release ophthalmic formulations and the method of treatment comprising administering such formulations topically to the eye when in need thereof.

Sustained release, and comfortable opthalmic composition and method for ocular therapy

This invention is directed toward a method of preparing a topical composition comprising ciprofloxacin and hydrocortisone. The method involves dispersing hydrocortisone with lecithin for greater than 45 minutes prior to combining hydrocortisone with the balance of the composition.

Process for manufacturing compositions containing ciprofloxacin and hydrocortisone

Suspension formulations containing dexamethasone and ciprofloxacin are disclosed. The formulations contain a nonionic polymer, a nonionic surfactant and an ionic tonicity agent, but are physically stable and easily re-suspended. The formulations are intended for topical application to the eye, ear or nose.

Topical suspension formulations containing ciprofloxacin and dexamethasone

Growing community of inventors

Arlington, TX, United States of America

Onkar N Singh